Silencing the Roadblocks to Effective Triple-Negative Breast Cancer Treatments by siRNA Nanoparticles

Endocrine-Related Cancer - United Kingdom
doi 10.1530/erc-16-0482
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

Oncotarget
Oncology
2014English

Layer-By-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment

ACS Nano
Materials ScienceNanoscienceEngineeringNanotechnologyAstronomyPhysics
2013English

Triple-Negative Breast Cancer

2018English

Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

2019English

Systemic Administration of siRNA With Anti-Hb-Egf Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer

English

HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Cancer Research
Cancer ResearchOncology
2013English

Metabolic Consequences of HIF Silencing in a Triple Negative Human Breast Cancer Xenograft

Oncotarget
Oncology
2018English

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy